DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Emkay picks JK Cement, Motilal Oswal, 2 more small & midcap stocks. 4 reasons why
22/05/2025
Kumar Mangalam Birla's Grasim gets cheapest rupee bond deal in 5 years
22/05/2025
Markets move fast, but compounding moves faster : A Balasubramanian on why the next decade will be transformational
22/05/2025
Gold prices rise for 4 consecutive sessions, gain by Rs 3,800. Check price prediction
22/05/2025
Tyre stocks are a safe bet amid auto sector uncertainty and falling rubber prices : Anshul Saigal
22/05/2025
Fund Manager Talk | Defence stocks rally shows FOMO taking over rationality, says Kotak's Atul Bhole
22/05/2025
